Novo Nordisk has said its connected durable insulin pens NovoPen® 6 and NovoPen Echo® Plus will be available across 50 countries starting in the first half of 2019. This will hopefully be followed by the delivery of connectivity for its disposable, pre-filled injection pens later in the year.
Novo Nordisk has also entered into partnerships with Dexcom, Glooko and Roche to help them advance the digital health solutions available for people living with diabetes and their healthcare professionals. Its aim is to seamlessly integrate insulin dosing data from connected pen devices with its partners' open ecosystems and diabetes management solutions, like data from blood glucose meters and continuous glucose monitoring systems.
“Novo Nordisk's durable insulin pens NovoPen® 6 and NovoPen Echo® Plus will be available across 50 countries starting in the first half of 2019. “
Marcel Gmuender, global head of Roche Diabetes Care, said: "Synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems."
Camilla Sylvest, EVP of Commercial Strategy & Corporate Affairs at Novo Nordisk, said: "Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes. We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals."